What are the side effects of Lanreotide (Somatostatin analogue)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Lanreotide can cause several side effects, including gastrointestinal issues, injection site reactions, gallbladder abnormalities, and metabolic effects, as reported in the most recent study 1.

Common Side Effects

  • Gastrointestinal issues such as diarrhea, abdominal pain, nausea, vomiting, and constipation
  • Injection site reactions like pain, redness, and swelling
  • Gallbladder abnormalities including gallstones
  • Metabolic effects, including high blood sugar or diabetes

Less Common Side Effects

  • Fatigue, headache, dizziness, and decreased thyroid function
  • Heart rhythm abnormalities, severe allergic reactions, and pancreatitis

Monitoring and Management

Patients should report persistent or severe side effects to their healthcare provider immediately, and regular monitoring of blood glucose, thyroid function, and gallbladder status is typically recommended during treatment, as suggested by 1. The dosage of lanreotide should be balanced between efficacy and side effects, with a dose of 120 mg every 4 weeks associated with greater reductions in liver volume, but more side effects, than a lower dose of 90 mg every 4 weeks 1.

Key Considerations

  • Most patients experience gastrointestinal discomfort during the first injections, which gradually fades over time 1
  • Therapy cessation after short-term treatment usually results in a relapse of liver growth, but patients who discontinued treatment can benefit from retreatment 1
  • The therapy is well tolerated, and serious adverse events leading to withdrawal are infrequent (<5%) 1

From the FDA Drug Label

1 Patients with any Adverse Reactions1579235686 Gastrointestinal disorders1217123557 Diarrhea81 48155 37 Abdominal pain34 2079 19 Nausea15 946 11 Constipation9 533 8 Flatulence12 730 7 Vomiting85287 Loose stools169236 In the pooled clinical studies of SOMATULINE DEPOT therapy, a variety of gastrointestinal (GI) reactions occurred, the majority of which were mild to moderate in severity. The most commonly occurring adverse reactions in the pooled analysis were:

  • Diarrhea
  • Abdominal pain
  • Cholelithiasis

    Other adverse reactions reported include:

  • Nausea
  • Constipation
  • Flatulence
  • Vomiting
  • Loose stools
  • Headache
  • Musculoskeletal pain
  • Injection site reaction
  • Hyperglycemia
  • Hypertension
  • Dizziness
  • Depression
  • Dyspnea These side effects are based on data from patients treated with lanreotide, as reported in the drug label 2.

From the Research

Lanreotide Side Effects

  • The most common toxicities associated with lanreotide include fatigue, diarrhoea, abdominal discomfort, and cholelithiasis 3
  • Exocrine Pancreatic Insufficiency (EPI) is a rare but serious complication of chronic use of somatostatin analogues, including lanreotide 4
  • EPI can lead to symptoms such as diarrhea, weight loss, and deficiency of vitamins and trace elements 4
  • Other side effects of lanreotide may include injection-site pain, hyperglycemia, and biliary disorders 4, 5
  • The safety profile of lanreotide is generally considered good, with no severe or unexpected toxicities reported compared to standard-dose somatostatin analogues 3

Disease Control and Response

  • Lanreotide has been shown to achieve significant rates of disease control, with disease control rates ranging from 30 to 100% 3
  • However, response rates are generally modest, with objective response rates ranging from 0 to 14% 3
  • Biochemical improvement and symptom improvement have been reported in some patients, with rates ranging from 23 to 100% and 27 to 100%, respectively 3

Treatment Recommendations

  • Lanreotide is often used in combination with other therapies, such as interferon or radioisotopes, to control hormone-related symptoms and disease growth 6
  • The optimal dosage and benefits of combination therapy with other molecules remain to be elucidated in further randomized studies 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.